Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma
Carcinoma, Renal Cell
Protein Kinase Inhibitors
Declining or stable rates of most AEs support an acceptable long-term safety profile for axitinib in patients with mRCC. However, increases in the rates of some AEs warrant monitoring. This analysis is limited in that it was retrospective and included a relatively small patient population.